Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346426 | 0.87 | BTK (0.64) | BTKCD69 | |
| SCHEMBL1066619 | 0.84 | BTK (0.63) | BTK | |
| SCHEMBL3346420 | 0.83 | BTK (0.62) | BTKCD69 | |
| SCHEMBL1203804 | 0.80 | BTK (0.80) | BTKCD69 | |
| SCHEMBL1065111 | 0.74 | BTK (0.56) | BTK | |
| SCHEMBL13305728 | 0.72 | BTK (1.00) | BTKCD69 | |
| SCHEMBL12637547 | 0.72 | BTK (0.64) | BTK | |
| SCHEMBL12637545 | 0.72 | BTK (0.64) | BTK | |
| SCHEMBL1069604 | 0.72 | BTK (0.64) | BTK | |
| SCHEMBL17957215 | 0.71 | BTK (0.66) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | claimed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947835-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2270200-A2 | Kinase inhibitors, and methods of using and identifying kinase inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2270200-A2 | Kinase inhibitors, and methods of using and identifying kinase inhibitors | CGI Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | BTK 1/4885CD69 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.